Clinical trials
Myopathy clinical trials
Below are recruiting myopathy clinical trials, each written for real people, not researchers. We’re tracking 121 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07511556RecruitingPhase 1/Phase 2
Study of UX016 for people with GNE myopathy
This study tests a new medicine called UX016 for people with GNE myopathy, a rare genetic muscle disease that causes weakness in the hands and legs. The trial aims to see if the medicine is safe and whether it can help improve muscle strength. It is the first time this medicine is being tested in humans.
Orange, CaliforniaAges 18–55 - NCT07486869RecruitingPhase 2
Emapalumab study for MDA5-related lung disease
This trial tests if emapalumab can help people with a serious lung condition linked to MDA5 antibodies. It may be an option for those with worsening breathing despite other treatments.
Miami, FloridaAges 18 years+ - NCT07478367Recruiting
Muscle weakness in hospitalized patients outside the ICU
This study looks at muscle weakness that can develop when you are in the hospital for an acute illness but not in the intensive care unit (ICU). It aims to understand how common this weakness is and what factors might be involved.
RozzanoAges Any age - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06833489Recruiting
Using genetic testing to find answers for rare muscle diseases
This study looks at leftover muscle tissue from people who have had genetic testing for rare muscle diseases but didn't get a clear diagnosis. The goal is to use newer genetic analysis to find the cause of their disease.
MarseilleAges Any age - NCT04920812Recruiting
Testing multi-sample methods to diagnose mitochondrial muscle disease
This study looks for the cause of suspected mitochondrial diseases by combining multiple lab tests on muscle and skin samples, plus genetic testing results. If your current gene tests didn’t find an answer, this could help researchers learn what might be causing your condition.
Nice, CHU de NICEAges Any age - NCT06786390Recruiting
Walking recovery after muscle weakness
This trial tests if a walking program combined with electrical stimulation can help people recover walking ability after critical illness. It is for patients who developed limb weakness in the hospital and were independent before their illness.
MilanAges 18–85 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07303335Enrolling by invitation
Sarcopenia in ICU patients on long-term ventilation
This study checks for muscle loss (sarcopenia) in ICU patients who need a breathing machine (mechanical ventilation). It aims to track how muscle health changes during hospital stay.
Terrassa, BarcelonaAges 18 years+ - NCT07293988Recruiting
Calf muscle stiffness in adults with cerebral palsy
This study looks at a type of muscle stiffness called spastic myopathy in adults with cerebral palsy. It tests whether a specific treatment or evaluation can help improve walking and calf muscle flexibility.
Créteil, Île-de-France RegionAges 18 years+ - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT07284797RecruitingPhase 1
Safety study for autoimmune disease and healthy volunteers
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
MelbourneAges 18–75 - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07229144RecruitingPhase 1
Study of OM336 for people with active autoimmune diseases
This trial tests a new treatment called OM336 for people with active autoimmune diseases that have not improved after at least two other treatments. The goal is to see if OM336 can help control the disease.
Hamilton, Waikato RegionAges 18–75 - NCT06696027Recruiting
Loss of Y chromosome in autoimmune and lung disease
This study looks at how the loss of the Y chromosome in blood cells may be linked to autoimmune and lung diseases in older men. By joining, you help researchers understand this connection better.
Bonn, North Rhine-WestphaliaAges 50 years+ - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT05454527Recruiting
Biobank study follow-up for adults with inflammatory muscle disease
This study follows adults who have (or are being evaluated for) inflammatory muscle conditions to collect health data and genetic test information. It may help researchers better understand these diseases and improve future care.
ParisAges 18 years+ - NCT07188285Enrolling by invitation
Immune system study for active autoimmune diseases
This study uses a blood test called mass spectrometry to look at the immune system in people with active autoimmune diseases. It aims to find patterns that could help doctors better understand and treat these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07160205RecruitingPhase 2/Phase 3
Study of ULSC for dermatomyositis and polymyositis
This trial tests a new treatment called ULSC to see if it can improve muscle strength and skin symptoms, and help reduce steroid use in people with dermatomyositis or polymyositis. It may be an option if standard treatments haven't worked well enough.
Gainesville, FloridaAges 18 years+
Hear when a new Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myopathy?
- Yes. Clin2 currently lists 121 recruiting myopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.